| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
34,250 |
33,240 |
$2.69M |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
9,775 |
9,715 |
$1.69M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
30,293 |
29,395 |
$1.19M |
| 62323 |
|
5,105 |
4,671 |
$1.00M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
16,308 |
16,228 |
$839K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
5,619 |
5,577 |
$755K |
| 99152 |
|
11,499 |
10,036 |
$493K |
| 64635 |
|
1,515 |
1,149 |
$357K |
| 62321 |
|
1,704 |
1,545 |
$348K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,896 |
2,894 |
$294K |
| 64493 |
|
2,453 |
1,158 |
$269K |
| 64636 |
|
1,577 |
1,133 |
$235K |
| 99406 |
|
18,374 |
17,735 |
$191K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
1,897 |
1,882 |
$188K |
| 27096 |
|
856 |
617 |
$164K |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
141 |
141 |
$100K |
| 64494 |
|
2,401 |
1,134 |
$96K |
| 64495 |
|
1,762 |
747 |
$79K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
990 |
987 |
$68K |
| 20610 |
|
1,608 |
1,249 |
$64K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
3,937 |
3,712 |
$62K |
| 64490 |
|
404 |
188 |
$48K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,331 |
2,143 |
$44K |
| 64633 |
|
181 |
146 |
$41K |
| 64634 |
|
180 |
145 |
$34K |
| 20553 |
|
590 |
576 |
$29K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
2,588 |
2,347 |
$22K |
| 77002 |
|
276 |
273 |
$20K |
| 99442 |
|
758 |
745 |
$17K |
| 99490 |
Ccm add 20min |
343 |
343 |
$16K |
| 64491 |
|
402 |
188 |
$14K |
| 99439 |
|
211 |
211 |
$10K |
| 64483 |
|
67 |
43 |
$9K |
| 64492 |
|
91 |
36 |
$4K |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
390 |
385 |
$3K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
8,686 |
7,836 |
$2K |
| 1036F |
|
21,083 |
20,265 |
$2K |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
4,195 |
3,901 |
$2K |
| 98977 |
|
54 |
54 |
$1K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
105 |
104 |
$1K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
14 |
14 |
$1K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
15 |
15 |
$137.48 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
42 |
41 |
$105.48 |
| G8428 |
Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given |
536 |
508 |
$74.99 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
16 |
16 |
$63.30 |
| 4004F |
|
3,767 |
3,630 |
$24.00 |
| 1123F |
|
220 |
212 |
$24.00 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
30 |
30 |
$5.47 |
| G9500 |
Radiation exposure indices documented in final report for procedure using fluoroscopy |
860 |
755 |
$0.88 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
4,286 |
4,139 |
$0.00 |
| G9561 |
Patients prescribed opiates for longer than six weeks |
221 |
205 |
$0.00 |
| G9368 |
At least two orders for high-risk medications from the same drug class not ordered |
613 |
591 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
4,022 |
3,899 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
1,049 |
1,017 |
$0.00 |
| G9577 |
Patients prescribed opiates for longer than six weeks |
221 |
205 |
$0.00 |
| G9562 |
Patients who had a follow-up evaluation conducted at least every three months during opioid therapy |
304 |
277 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
272 |
263 |
$0.00 |
| 1124F |
|
263 |
246 |
$0.00 |
| M1210 |
At least two orders for high-risk medications from the same drug class, (table 4), not ordered |
132 |
129 |
$0.00 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
47 |
44 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
146 |
131 |
$0.00 |
| 4040F |
|
66 |
64 |
$0.00 |
| G9991 |
Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period |
26 |
26 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
1,162 |
1,121 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
2,952 |
2,842 |
$0.00 |
| G9642 |
Current smoker (e.g., cigarette, cigar, pipe, e-cigarette or marijuana) |
326 |
320 |
$0.00 |
| M1007 |
>=50% of total number of a patient's outpatient ra encounters assessed |
2,881 |
2,758 |
$0.00 |
| G2197 |
Patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user |
3,146 |
3,022 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
1,167 |
1,125 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
405 |
383 |
$0.00 |
| G9366 |
One high-risk medication not ordered |
31 |
30 |
$0.00 |